AbbVie (ABBV) performed a chapeau instrumentality Friday — beating and raising for the 3rd clip successful 2021 — and AbbVie banal inched person to a bargain constituent successful aboriginal action.
X
The income bushed was mostly driven by AbbVie's immunology and aesthetics franchises, Piper Sandler expert Christopher Raymond said successful a study to clients. AbbVie's biggest moneymaker, inflammatory cause Humira, brought successful $5.43 cardinal successful sales, good supra forecasts for $5.26 billion, helium said.
But successful conjunction with its net report, AbbVie unveiled mixed trial results for its drug, Vraylar, successful patients with depression. The cause missed its extremity successful 1 study, and lone a debased dose met the extremity of a 2nd study. Vraylar is already approved successful schizophrenia and bipolar treatment.
"It is not uncommon to spot mixed information for drugs successful (major depressive disorder), fixed the heterogenous and subjective quality of the disease," Mizuho Securities expert Vamil Divan said successful his study to clients. He noted AbbVie inactive plans to inquire for Food and Drug Administration approval.
In greeting trading connected today's banal market, AbbVie banal roseate 3.8% adjacent 113.80. AbbVie banal is forming a flat base with a buy point astatine 121.63, according to MarketSmith.com.
AbbVie Stock: Earnings, Sales Top
During the 3rd quarter, AbbVie earned $3.33 per stock — minus immoderate items — connected $14.34 cardinal successful sales. Earnings precocious astir 18% and income roseate 11% twelvemonth implicit year. Both measures bushed analysts' telephone for nett of $3.21 per stock and $14.3 cardinal successful sales, according to FactSet.
By segment, the biggest maturation came from AbbVie's aesthetics portfolio — courtesy of its Allergan buyout. Overall, aesculapian aesthetics income surged much than 29% connected a strict as-reported ground to $1.25 billion. Botox accounted for $545 million, beating views for $502 million, Piper Sandler's Raymond said. On a year-over-year basis, cosmetic Botox income soared astir 39%.
Sales of immunology drugs, which includes Humira, jumped much than 15% to $6.67 billion. That included Skyrizi and Rinvoq, some of which topped projections, Raymond said. Psoriasis attraction Skyrizi brought successful $796 million. Rinvoq, which treats rheumatoid arthritis, generated $453 million.
Mizuho's Divan noted AbbVie banal investors are awaiting further clarity connected the aboriginal of Rinvoq. The FDA precocious said Rinvoq and different drugs successful its people would person to see an further informing connected their statement against heart-related events, cancer, humor clots and death.
"But we are encouraged by the company's continued beardown show and outlook," helium said. He kept his bargain standing connected AbbVie stock.
AbbVie Raises 2021 Earnings View
Less bullishly, income of AbbVie crab cause Imbruvica came successful abbreviated astatine $1.37 billion. Analysts called for $1.43 billion, Piper Sandler's Raymond said.
The neuroscience conception was besides mixed. Botox brought successful $645 cardinal successful income arsenic a therapeutic for migraines and different conditions. That topped forecasts for $589 cardinal and grew northbound of 23%. But income of Vraylar and Parkinson's cause Duodopa came successful light.
AbbVie raised its full-year net outlook by 8 cents per share, astatine the midpoint, to $12.63-$12.67 a share. That bushed AbbVie banal analysts' projection for $12.59 per share. The Street besides forecast $56.2 cardinal successful sales.
Follow Allison Gatlin connected Twitter astatine @IBD_AGatlin.
YOU MAY ALSO LIKE:
Alnylam Stock Dives As Sales Growth Falters And CEO John Maraganore Plans Exit
How Merck's Antiviral Covid Pill Could Add To Its Already Bullish 2021 Outlook
Get Timely Buy & Sell Alerts With IBD Leaderboard
How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
Options Trading: How To Start Using Options, How To Manage Risk
English (US) ·